NVCR News and Press, NovoCure Limited From 11/11/20

Novocure (NVCR) has received the CE Mark for the NovoTTF-100L system, for the commercialization of the device as a first-line treatment in combination with Eli Lilly's Alimta (pemetrexed) and platinum-based chemotherapy for malignant pleural mesothelioma ((MPM)), in the Europea...

Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investo...

Provides flexible capital structure prior to anticipated period of significant innovation and growth Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 millio...

Initial conversion price represents a premium of approximately 50% Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the closing of its previously announced offering of $575 million ...

Novocure (NVCR) has priced $500M of its 0% convertible senior unsecured notes due November 1, 2025 through a private placement.Initial purchasers granted an option to purchase additional $75M of notes.Closing date is November 5. Special interest on the notes, if any,  will be payabl...

Initial conversion price represents a premium of approximately 50% Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount of its 0% C...

Novocure (NVCR) to offer $500M of convertible senior notes due 2025, via a private placement. Initial purchasers have an option to purchase up to an additional $75M notes.Net proceeds will be used to further advance the company's clinical and product development programs and to invest in asso...

Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”). The notes will ...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q3 2020 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q3 2020 Earnings Call Transcript

Novocure Ltd (NVCR) Q3 2020 Earnings Conference Call October 29, 2020, 08:00 ET Company Participants Gabrielle Fernandes - Director, IR William Doyle - Executive Chairman Asaf Danziger - President, CEO & Director Ashley Cordova - CFO & VP, IR Ely Benaim - Chief Medical Officer Uri Wei...